Apigenin: Technical Guidelines for Malignant Mesothelioma Research

What This Product Solves

Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) addresses the need for a well-characterized histone deacetylase (HDAC) inhibitor for cancer research, specifically in the context of malignant mesothelioma (MM). This flavonoid is supported by product-level evidence for modulating cell growth, apoptosis, and DNA damage response in both in vitro and in vivo models. Researchers can apply Apigenin to mechanistic studies of apoptosis induction via HDAC inhibition, reactive oxygen species production, and DNA damage signaling, while maintaining strict control over dosing and solubility parameters. The compound is not suitable for diagnostic or therapeutic applications.

Protocol Parameters

• Cell proliferation inhibition assay | 12.5–50 μM (dose range) | In vitro malignant mesothelioma cell lines (MM-B1, MM-F1, H-Meso-1) | Captures dose- and time-dependent inhibition of cell growth; significant effects at 48–72 h | product_spec [product_url]
• HDAC inhibition (apoptosis induction) | IC50: 34–49 μM | In vitro assessment of HDAC activity and apoptosis markers | Quantifies potency and supports mechanistic studies of apoptosis induction via HDAC inhibition | product_spec [product_url]
• In vivo tumor suppression | 20 mg/kg (intraperitoneal) | C57BL/6 mouse model bearing MM #40a cells | Dose and route shown to reduce tumor growth and prolong survival vs. vehicle controls | product_spec [product_url]
• Compound solubility | ≥9.8 mg/mL in DMSO (insoluble in water/ethanol) | Stock preparation for cell-based and in vivo assays | Ensures accurate dosing; warming at 37°C or ultrasonic shaking recommended for dissolution | product_spec [product_url]
• Stock storage and handling | Store at -20°C; use freshly prepared stocks | All experimental workflows | Minimizes degradation and maintains compound integrity | workflow_recommendation

Workflow Setup and QC Checklist

• Solubility preparation: Dissolve Apigenin in DMSO at concentrations ≥9.8 mg/mL. For difficult dissolution, warm to 37°C or use ultrasonic agitation. Confirm clarity before dilution into assay media.
• Vehicle control setup: Match the final DMSO concentration in all experimental arms, including controls, to isolate compound-specific effects.
• Cell line selection: Use validated malignant mesothelioma cell lines (e.g., MM-B1, MM-F1, H-Meso-1) for consistency with product dossier parameters.
• Dosing windows: For proliferation and apoptosis assays, apply Apigenin at 12.5–50 μM and incubate for 48–72 hours. Monitor cell viability and morphology at interim timepoints to preempt off-target cytotoxicity.
• In vivo protocols: If applicable, administer 20 mg/kg intraperitoneally in C57BL/6 mice, ensuring compound is freshly prepared and delivered at a consistent time of day to minimize variability.
• Storage and QC: Aliquot Apigenin stocks to minimize freeze-thaw cycles; store at -20°C and avoid prolonged exposure to ambient or light.
• Documentation: Record batch numbers, lot-specific molecular weights, and preparation dates for reproducibility.

Common Failure Modes and Fixes

• Poor dissolution in DMSO: Increase temperature to 37°C or apply ultrasonic agitation. Avoid water or ethanol, as Apigenin is insoluble in these solvents (product_spec).
• Loss of activity on storage: Use freshly prepared stocks and avoid repeated freeze-thaw cycles. Store at -20°C as per workflow recommendations.
• Precipitation in assay medium: Ensure complete dissolution before dilution, and add Apigenin to media slowly with constant mixing to prevent precipitation.
• Off-target cytotoxicity: Include DMSO-only controls and titrate dosing based on cell line sensitivity and target window (12.5–50 μM for in vitro work).
• Batch variability: Document all stock preparations, and harmonize protocols across experimental runs to reduce inter-assay variability.

Scope and Limitations

All quantitative and protocol guidance for Apigenin is derived from product specifications and workflow recommendations rather than peer-reviewed articles or clinical datasets. The compound's activity has been characterized primarily in malignant mesothelioma cell lines and C57BL/6 mouse models, with endpoints focused on apoptosis induction, HDAC inhibition, reactive oxygen species production, and DNA damage response. Use outside these validated contexts (including diagnostic or therapeutic applications) is not supported by the available product data. Researchers should not extrapolate protocol parameters to unrelated cell types or in vivo models without additional pilot testing. Apigenin is intended strictly for scientific research and is not suitable for clinical or diagnostic workflows.

Conclusion

Apigenin (SKU N1828) is a plant-derived HDAC inhibitor suitable for mechanistic and phenotypic studies in malignant mesothelioma research. Proper solubility handling, dosing, and storage are essential to ensure reproducible results. For detailed compound specifications and ordering, refer to the Apigenin product page from APExBIO. This workflow-focused guide is based solely on product dossier evidence and best-practice recommendations for laboratory use.